- Biogen Idec (BIIB)
- Neurocrine Biosciences (NBIX)
- Vion Pharmaceuticals (VION)
- Panacos Pharmaceuticals (PANC)
- Discovery Labs (DSCO).
John C. writes: "Is Biogen Idec a good buy right now? It's up over 34% for the year. Do you think it will keep trending upward? I don't see a lot of insider buying." Biogen Idec has had a rock-star year. As I write this, with shares trading at $65.66, the stock is up 33% year to date, up 53% from its March low. No other big-cap biotech stock has performed as well in 2007. Gilead Sciences ( GILD) and Celgene ( CELG) have done very well, but they only take the silver and bronze; Biogen Idec is the gold medalist.